Dabrafenib is an oral kinase inhibitor marketed as Tafinlar for BRAF V600 mutation-positive cancers in specified settings, as monotherapy and frequently in combination with trametinib. U.S. labeling includes melanoma, NSCLC, anaplastic thyroid cancer, certain solid tumors, and pediatric low-grade glioma indications. Initial U.S. approval was in 2013.
Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.
A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07110246 |
Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas |
RECRUITING | PHASE2 |
| NCT06475989 |
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer |
RECRUITING | PHASE3 |
| NCT04940052 |
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04116541 |
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. |
RECRUITING | PHASE2 |
| NCT03975829 |
Pediatric Long-Term Follow-up and Rollover Study |
RECRUITING | PHASE4 |
| NCT03149029 |
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT02465060 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT01989585 |
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma |
ACTIVE_NOT_RECRUITING | PHASE1/PHASE2 |
| NCT01947023 |
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT01682083 |
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). |
COMPLETED | PHASE3 |
